Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01620229)
This phase I/II trial studies the side effects and best way to give brentuximab vedotin (also known as SGN-035) and to see how well it works after donor stem cell transplant in treating patients with hematologic malignancies.
Monoclonal antibodies (mAbs), including antibody-drug conjugates or ADCs such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Monoclonal antibodies may kill cancer cells that are left after donor stem cell transplant.
This trial is sponsored by Fred Hutchinson Cancer Research Center. 
- Condition: Hematopoietic/Lymphoid Cancer
- Drugs used in this trial
- Phase: I & II
- Enrollment: 0
- Start: June 2013
- Primary Completion: April 2014 (Final data collection date for primary outcome measure)
- Last verified: April 2014
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.